- Home
- PIM vs OBIO Comparison
PIM vs OBIO Comparison
Compare PIM & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIM
- OBIO
- Stock Information
- Founded
- PIM 1988
- OBIO 2017
- Country
- PIM United States
- OBIO United States
- Employees
- PIM N/A
- OBIO N/A
- Industry
- PIM Finance Companies
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- PIM Finance
- OBIO Health Care
- Exchange
- PIM Nasdaq
- OBIO Nasdaq
- Market Cap
- PIM 168.6M
- OBIO 147.8M
- IPO Year
- PIM N/A
- OBIO N/A
- Fundamental
- Price
- PIM $3.50
- OBIO $2.60
- Analyst Decision
- PIM
- OBIO Strong Buy
- Analyst Count
- PIM 0
- OBIO 4
- Target Price
- PIM N/A
- OBIO $14.00
- AVG Volume (30 Days)
- PIM 57.5K
- OBIO 261.5K
- Earning Date
- PIM 01-01-0001
- OBIO 11-11-2025
- Dividend Yield
- PIM 8.28%
- OBIO N/A
- EPS Growth
- PIM N/A
- OBIO N/A
- EPS
- PIM 0.05
- OBIO N/A
- Revenue
- PIM N/A
- OBIO $2,944,000.00
- Revenue This Year
- PIM N/A
- OBIO $19.83
- Revenue Next Year
- PIM N/A
- OBIO $12.53
- P/E Ratio
- PIM $63.80
- OBIO N/A
- Revenue Growth
- PIM N/A
- OBIO 41.61
- 52 Week Low
- PIM $2.90
- OBIO $2.37
- 52 Week High
- PIM $3.28
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- PIM 72.22
- OBIO 44.18
- Support Level
- PIM $3.43
- OBIO $2.57
- Resistance Level
- PIM $3.50
- OBIO $2.79
- Average True Range (ATR)
- PIM 0.04
- OBIO 0.15
- MACD
- PIM 0.02
- OBIO -0.00
- Stochastic Oscillator
- PIM 97.22
- OBIO 10.50
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.